Topic: checkpoint inhibitors
CytomX's R&D update includes the news that partner Bristol-Myers Squibb has dropped three programs, putting pressure on the biotech's share price.
The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors.
Bristol-Myers is testing its leukemia therapy Sprycel in a phase 2 combo study with the anti-PD-1 drug Opdivo in non-small cell lung cancer patients.
A new screening system confirmed that an emerging class of cancer drugs called IAP antagonists have immune-boosting powers.
Scientists have early evidence that Amgen's oncolytic virus plus PD-1 and MEK inhibitors could be effective in treating melanoma.
Having failed to improve outcomes in metastatic NSCLC, the anti-CTLA4 antibody has now missed the mark in a phase 3 head and neck cancer trial.
Alphamab Oncology has raised $100 million to advance a broad pipeline of treatments for infertility, ophthalmology and infection, as well as oncology.
Combining a RIP1 inhibitor with Merck's hit checkpoint inhibitor Keytruda holds promise in treating pancreatic cancer, GSK says.
SITC kicked off with a stack of new data on immuno-oncology drugs, including a first look at Merck’s early-stage drugs targeting LAG-3 and TIGIT.
The Big Pharma is investing $12 million in Compugen as part of a deal that gives it the right to first negotiations for the COM701 license.